CDT Equity Inc. (CDT) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Reporting Period: Quarter ended June 30, 2025.
Company Overview: CDT Equity Inc. (formerly Conduit Pharmaceuticals Inc.) is a data-driven biotech development company focused on identifying and advancing high-potential therapeutic assets, particularly deprioritized clinical-stage compounds. The company leverages AI, solid-form chemistry, and asset repositioning. Effective August 5, 2025, the company officially changed its name to CDT Equity Inc.
Capital Structure: As of August 14, 2025, there were 3,062,025 shares of common stock outstanding. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(6,028) | $(10,781) | $(8,935) |
| Operating Loss | $(4,952) | $(8,568) | $(6,095) |
| R&D Expenses | $1,860 | $2,776 | $153 |
| G&A Expenses | $3,092 | $5,792 | $5,942 |
| Cash and Equivalents (End of Period) | $3,332 | $3,332 | $219 |
| Net Cash Used in Operating Activities | N/A | $(6,509) | $(3,870) |
| Net Cash Provided by Financing Activities | N/A | $9,684 | $113 |
| Total Assets | $7,989 | $7,989 | $4,193 |
| Total Liabilities | $4,460 | $4,460 | $10,986 |
| Stockholders' Equity | $3,529 | $3,529 | $(6,793) |
Material Changes vs. Prior Period
- Significant Increase in R&D Spend: R&D expenses surged to $1.86 million in Q2 2025 from $25,000 in Q2 2024. This 7,340% increase is primarily driven by new service agreements with related party Sarborg Limited ($1.6 million) and consulting fees.
- Debt Reduction and Conversion: The company significantly reduced its debt load. The August 2024 Nirland Note was fully repaid or converted by February 2025. The A.G.P. Convertible Note (principal $5.7 million) saw partial conversions totaling approximately $2.2 million in principal/interest during the six months ended June 30, 2025, leaving approximately $3.6 million outstanding.
- Equity Position Improvement: Stockholders' equity turned positive ($3.5 million) from a deficit of $(6.8 million) at year-end 2024. This was driven by an At-The-Market (ATM) offering raising $11.9 million in proceeds and the conversion of debt to equity.
- Reverse Stock Splits: The company executed a 1-for-100 reverse split in January 2025 and a 1-for-15 reverse split in May 2025. All historical share data has been retroactively adjusted.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has concluded there is substantial doubt regarding the company's ability to continue as a going concern for at least 12 months from the filing date. The company has an accumulated deficit of $39.9 million and requires additional funding to support its business plan.
- Liquidity Strategy: The company plans to fund operations through the remaining $8.0 million available under its ATM Sales Agreement and potential public/private equity or debt financings. Management estimates a working capital requirement of approximately $12.7 million for the next 12 months.
- Unusual Items:
- Gain on Debt Extinguishment: Recorded a $278,000 gain on the settlement of a convertible promissory note.
- Waiver of Accrued Interest: Recorded a $371,000 gain due to the waiver of accrued interest on the A.G.P. Convertible Note.
- Loss on Fair Value Changes: Recorded a $2.9 million loss on the change in fair value of convertible notes payable for the six months ended June 30, 2025.
- Risks and Contingencies:
- Legal Proceedings: A claim by Strand Hanson Limited seeking $2 million and shares is scheduled for trial in October 2025. A $400,000 contingency has been accrued. Additionally, there is an ongoing dispute with St. George Street Capital regarding the ownership of the AZD 1656 co-crystal patent; no loss has been accrued as the outcome is not considered probable.
- Nasdaq Compliance: The company regained compliance with Nasdaq listing rules in May 2025 and transferred its listing to the Nasdaq Capital Market.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $3.3 million cash balance against the stated $12.7 million working capital requirement for the next 12 months.
- ATM Program Status: Confirm the remaining $8.0 million capacity under the Sales Agreement and the terms of future sales.
- Related Party Transactions: Review the terms and valuation of the Sarborg Service Agreement and Additional Agreement, which accounted for a significant portion of R&D expenses.
- Debt Conversion Terms: Analyze the remaining $3.6 million outstanding on the A.G.P. Convertible Note and the potential dilution upon full conversion.
- Legal Exposure: Monitor the outcome of the Strand Hanson Limited trial and the St. George Street Capital patent dispute.
- Internal Controls: Note that disclosure controls and procedures were deemed ineffective due to material weaknesses not yet remediated.